PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

VOLUME 48, 1994
SUBJECT AND AUTHOR INDEX

PERGAMON

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editor-in-Chief

MATTHEW J. WAYNER

Division of Life Sciences, The University of Texas at San Antonio, San Antonio, TX 78249-0662

European Editor-in-Chief

SANDRA E. FILE

Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital
P.O. Box 3448, London SE1 9QH, UK

Editorial Advisory Board

LIISA AHTEE, Helsinki, Finland
LEMBIT ALLIKMETS, Tartu, Estonia
ROBERT L. BALSTER, Richmond, VA
GIOVANNI BIGGIO, Cagliari, Italy
MIKE BRILEY, Castres, France
ALLAN C. COLLINS, Boulder, CO
DONALD V. COSCINA, Toronto, Ontario, Canada
JACQUELINE N. CRAWLEY, Bethesda, MD
ANNETTE DOMENEY, Geneva, Switzerland
ADRIAN J. DUNN, Shreveport, LA
BURR EICHELMAN, Philadelphia, PA
WILLIAM J. FREED, Washington, DC
MANUEL FREIRE-GARABEL, Santiago De Compostella, Spain
RICHARD A. GLENNON, Richmond, VA
F. G. GRAEFF, São Paulo, Brazil
M. R. C. GREENWOOD, Davis, CA
ROLAND R. GRIFFITHS, Baltimore, MD
STEPHEN G. HOLTZMAN, Atlanta, GA
AKIRA HORITA, Seattle, WA
CHRIS E. JOHANSON, Baltimore, MD
HAROLD KALANT, Toronto, Ontario, Canada
G. JEAN KANT, Washington, DC
KATHLEEN M. KANTAK, Boston, MA
GEORGE F. KOOB, La Jolla, CA
CONAN KORNETSKY, Boston, MA
J. DAVID LEANDER, Indianapolis, IN
EMINY H. Y. LEE, Taipei, Taiwan
ALLEN S. LEVINE, Minneapolis, MN
WILLIAM J. McBRIDE, Indianapolis, IN
DONALD E. McMILLAN, Little Rock, AR
JACK H. MENDELSON, Belmont, MA
FATHY S. MESSIHA, Grand Forks, ND
ROBERT D. MYERS, Greenville, NC
JUDITH A. PRATT, Glasgow, UK
JAQUELINE SAGEN, Chicago, IL
ROSARIO SAMANIN, Milan, Italy
HERMAN H. SAMSON, Winston-Salem, NC
PAUL R. SANBERG, Tampa, FL
PHIL J. SKOLNICK, Bethesda, MD
LINDA P. SPEAR, Binghamton, NY
CLARE STANFORD, London, UK
MARIE-HÉLÈNE THIÉBOT, Paris, France
DEREK VAN DER KOOY, Toronto, Ontario, Canada
JEANNE M. WEHNER, Boulder, CO
BRUNO E. WILL, Strasbourg, France
J. C. WINTER, Buffalo, NY
ALICE M. YOUNG, Detroit, MI
IAN S. ZAGON, Hershey, PA

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editorial Office:
Matthew J. Wayner
Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West
San Antonio, TX 78249-0662
Fax: (210) 691-4510

European Editorial Office:
Sandra E. File
Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital
P.O. Box 3448, London SE1 9QH, UK
Fax: 44-(0)71-955-4627

Production Editor:
Alayne A. Bakken
E-mail: A.BAKKEN@ELSEVIER.COM

Publishing, Subscription, and Advertising Offices:
Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA, E-mail Address: ESUK.USA@ELSEVIER.COM; and Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England

Published Monthly

Annual Institutional Subscription Rates (1994): North, Central and South America, US$1440.00, Rest of World £935.00. Associated Personal Subscription Rates are available on request for those whose institutions are library subscribers. Sterling prices exclude VAT. Non-VAT registered customers in the European Community will be charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to change without notice.

Pharmacology Biochemistry and Behavior is an official journal of the International Behavioral Neuroscience Society. For information about the society, please contact: Dr. Linda Spear, Department of Psychology, State University of New York at Binghamton, Box 6000, Binghamton, NY 13902-6000, USA. Members of the International Behavioral Neuroscience Society may order personal subscriptions at a concessional rate; details of this rate are available upon request.

Pergamon

Pharmacology Biochemistry and Behavior, Vol. 48, No. 4, pp. I–VIII, 1994
Copyright © 1994 Elsevier Science Ltd
Printed in the USA. All rights reserved
0091-3057/94 $6.00 + .00

SUBJECT INDEX

Aδ fibers, 447
Absence epilepsy, 547, 575
Acetic acid, 371
Acetylcholine, 417, 613
Acoustic startle response, 307
ACTH, 429
Active avoidance, 805
Activity, 581
Acute dependence, 397
Adenylate cyclase, 983, 991
Adrenal demedullation, 887
Adrenal gland, 977
Adrenaline, 887
Age factors, 999
Aging, 575
Agonists, 241
Alcohol, 105, 999
Alcohol preference, 105
α_1-Adrenoceptor agonists/antagonists, 601
α-Helical CRF_{9-41}, 497
Alpha-helical $CRH_{(9-41)}$, 887
α-Methyl-*p*-tyrosine
Alpha-Methyl-5-HT, 315
Alpha-methyl-para-tyrosine, 93
Alprazolam, 69, 845
Amnesia, 971
AMPA antagonists, 111
Amphetamine, 23, 63, 161, 459, 581, 681, 839, 853, 1005, 1019
Amygdala, 307, 677
Analgesia, 57, 87, 357, 411
Anesthesia, 547
Animal model(s), 403, 1025, 671
Anorectic agents, 371
Anorexia, 601
Antagonism, 275
Antagonists, 241, 1019
Anterograde amnesia, 805
Anticonvulsant, 765
Antidepressant, 47, 119, 845
Antinociception, 37, 175, 699
Antiserum, 699
Anxiety, 223, 281, 307, 525, 893, 959
Anxiety model, 497
Anxiolytic, 497
Apomorphine, 423, 799, 839, 1053
Ascorbic acid, 161
Aspirin, 1047
Assay, 813
Ataxia, 111
Attention, 23, 935
Autoshaping, 1025

BALB/C, 497
Barbiturate, 593
Basal ganglia, 235, 441
BC 264, 363
Behavior, 119
Behavior genetics, 733
Behavioral depression, 845
Behavioral development, 447
Behavioral history, 491
Behavioral sensitization, 151, 265, 587
Behavioral suppression, 281, 959
Behavioral tolerance, 265
Behavioural observations, 259
Benzodiazepine receptor, 553, 765
Benzodiazepine(s), 357, 69, 223, 535
β-Adrenoceptors, 971
β-Endorphin, 563, 699
Beta-blocking drugs, 965
Binding protein, 813
Binge eating, 1025
Biotelemetry, 703
Blood alcohol, 105
Blood levels, 715
Blood pressure, 429, 899
Body weight, 357
Bombesin, 881
Brain, 87
Brain injury, 773
Brain stimulation, 487
Branched-chain amino acids, 101
Bretazenil, 397
Broiler chicks, 371
Bromocriptine, 839, 853
Buprenorphine, 723
Buspirone, 315
Butorphanol tartrate, 1025
BW2258U89, 809

C57BL mice, 327
C57BL/6J, 169
C57BL/6J, 733
C fibers, 447
Ca^{2+} antagonist, 613
Cadmium, 543
Caffeine, 217, 899
Caffeine pharmacokinetics, 337
Caffeine tolerance, 337
Calcium, 37
Calcium antagonist, 575
Calcium currents, 77
cAMP, 813
Carbachol, 93
Carbohydrate intake, 193
Carbon monoxide (CO), 9
Castration, 265, 515
Catalepsy, 357, 605
Catecholamines, 621, 773
CCK, 275
CCK-B receptors, 363
Cecum, 371
Cerebral protection, 613
CGP 39551, 571
Chemical adrenalectomy, 977
Chick, 971, 1047
Chickens, 479
Chlomipramine, 1037
Chlordiazepoxide, 397
Cholecystokinin, 363, 479, 809, 1019
Cholinergic system, 93
Chronic, 755
Chronic administration, 575
Chronic exposure, 643
Chronic treatment, 119
Cigarettes, 539
Cirazoline, 601
Circadian rhythm, 709
Circling, 681
cis-Flupenthixol, 681
Citalopram, 315
Clobazam, 765
Clonazepam, 765
Clonidine, 93
Clozapine, 253
CO_2, 345
Cocaine, 151, 169, 217, 265, 327, 403, 453, 473, 487, 491, 511, 715, 733, 909, 915, 1025
Coffee, 899
Cognition, 235
Color and position discrimination, 935
Conditioned fear, 525
Conditioned individual preference, 677
Conditioned place preference, 459, 677
Conditioned taste aversion(s), 601, 635
Conditioned taste preference, 651
Conditioning, 479, 791
Conspecific discrimination, 677
Context-specific, 791
Copulation, 423
Copulatory behavior, 1011
Core body temperature, 703
Core temperature, 119
Corticosterone, 53, 977
Cortisol, 377
CRF, 497, 1031
Crosstolerance, 765
Current, 915
Current-frequency trade-off, 557
Cyclic AMP, 37

D_1, 741
d-Amphetamine, 465, 787, 1053
DBA mice, 327
DBA/2J, 169
DBA/2J, 733

D-CPP-ene, 587
D-Cycloserine, 351
Delay-to-reinforcement, 47
Delayed matching-to-sample, 935
Delayed-matching-to-sample, 183
Delayed memory loss, 971
Δ^9-tetrahydrocannabinol, 1011
Dependence, 535
Desipramine, 47, 315
Devazepide, 275, 1019
Development, 403
DFP, 703
Diazepam, 183, 535, 557, 665, 765, 787
Diet, 57
Differential outcomes, 183
Differential rearing, 459
Differential reinforcement of low response rate, 69
Differing ages, 87
Dimethylxanthines, 337
Discrimination, 1041
Diuresis, 63
Dizocilpine, 9, 723
DNA synthesis, 709
DOI, 383, 1041
DOI-HCl, 315
DOPAC, 297, 515
Dopamine, 9, 43, 53, 141, 235, 241, 423, 515, 521, 525, 581, 605, 621, 651, 671, 681, 741, 781, 791, 853, 915, 1005, 1011, 1031, 1053
Dopamine agonist, 531
Dopamine antagonists, 817
Dopamine D_1 receptor, 465
Dopamine D_2 receptor(s), 465, 781
Dopamine D_3 receptor, 531
Dopamine extracellular output, 351
Dopamine receptor subtypes, 151
Dopamine receptors, 465
Dopamine transporter, 327
Dopamine uptake inhibitor, 135
Dopamine, reuptake, 817
Dopamine-mediated behaviors, 351
Dopaminergic agonists, 839
Dorsal raphe nucleus, 1041
Drinking, 63
Drinking behavior, 105
Drug abuse, 977
Drug discrimination learning, 635
Drug discrimination, 275, 473, 531
Drug reward, 459
Drug sensitization, 1005
Duration, 253

Ear-scratch response, 383
ECS, 315
Edema, 1037
Edothethelin, 1031
EEG, 259
8-OHDPAT, 315
Electrical stimulation, 1041
Electronic diary, 899
Electrophysiology, 983, 991
Elevated plus-maze, 689, 959
Endogenous bovine satiety agent, 17
Environmental enrichment, 459
Environmentally induced oral stereotypies, 241
Epidepride, 327
Epilepsy, 553
Epithelium, 709
Estrogen, 417
Estrous cycle, 417
Ethanol, 31, 141, 229, 297, 543, 593, 893, 929
Ethanol preference, 977
Ethanol reinforced behavior, 141
Ethological analysis, 959
Ethyl, 999
Excitatory amino acid(s), 9, 693
Exercise, 563
Exploration, 291, 839, 1053
Extinction, 217
Eye opening, 447

Fatty acid composition, 1047
Fawn-hooded rats, 105
Fear, 307
Feed restriction, 371
Feeding, 63, 135, 875
Feeding behavior, 809
Female, 909
Fenfluramine, 105, 875
Fentanyl, 547
Field experiment, 899
Fischer-344 male rats, 411
5,7-DHT, 315
5-HT, 223, 875, 971
5-HT_{1A} receptor agonists, 281
5-HT_{1A} receptors, 959
5-HT_{1B} receptors, 971
5-HT_2 agonist(s), 805, 1041
5-HT_2 antagonist, 613
5-Hydroxytryptamine, 1041
Fixed ratio, 253
Fixed-interval (FI), 69, 853
Fixed-interval schedule, 209, 491
Fixed-ratio, 69
Fixed-ratio schedule, 209, 511
Flesinoxan, 959
Fluanisone, 547
Flumazenil, 69
Flunitrazepam, 665
Fluoxetine, 411
Fluphenazine, 605
Fluvoxamine, 845
Focal ischemia, 77
Food consumption, 119
Food deprivation history, 1025
Food intake, 17, 809
Food reinforcement, 935
Food restriction, 241
Foot shocks, 307
Forced swimming test, 43
Forskolin, 37, 813
Fourth ventricle, 749
Fowls, 241
FRL rats, 703
Functional recovery, 773

G-Proteins, 37
GABA, 613, 893
$GABA_A$-benzodiazepine receptor complex, 69
GABA-receptor complex, 101
Ganglionic blockade, 887
Gastric ulcers, 53
Gastrin-releasing peptide, 809
Gastrointestinal tract, 371
GBR 12909, 135, 327, 817
GBR-12909, 915
GBR 12935, 733
Generalization, 635
Genetic epilepsy model, 547, 575
Genetics, 593
Gepirone, 301
Gerbils, 983, 991
Glue thinner, 661
Glutamate, 259, 587
Glutamatergic AMPA/kainate receptors, 437
Glutamic acid, 203
Glutathione, 845
Gonadal hormones, 265
Grooming, 1031
Growth, 709, 1047
Growth factors, 709

Habituation, 839
Haloperidol, 63, 151, 161, 671
Hamsters, 791
Head-twitch response, 383
Headache, 899
Heart rate, 703, 899
Hemiplegia, 773
Hexamethonium, 887
Hippocampus, 1053
HMPAO, 553
Hole blocking, 539
Hormone, 977
Hot plate, 357
HPLC purification, 17
HPNS, 259
Human, 899
Human subjects, 715
Huntington's disease, 441
Hydrogen peroxide, 845
Hyperactivity, 921
Hyperalgesia, 411, 1037
Hypercholinergic FSL rats, 703
Hypnorm, 547

Ibotenic acid lesion, 127
ICS 205930, 193
ICSS reward, 915
Imipramine, 47, 845
Immobilization stress, 297
Immune response, 53
In vivo binding, 69
In vivo microdialysis, 9
Incremental repeated acquistion, 935
Individual behavior, 839
Individual differences, 581, 1019
Inescapable shock, 845
Inflammation, 1037
Ingestive behavior, 875
Intensification by hypoglycemia of morphine dependence, 571
Intoxication, 229
Intracranial self-administration, 625
Intracranial self-stimulation, 661
Intracranial stimulation, 1005
Intragastric, 651
Intraparabrachial injection, 127
Intravenous, 1025
Intraventricular, 881
Intrinsic neurons, 127
Iomazenil, 553
Iron deficiency, 621

Juveniles, 909

Kappa opiate receptors, 87
Ketamine, 175, 755
Ketanserin, 383
Key pecking, 491
Kindling, 31, 553

L365-260, 1019
L-365,260, 275
Lamotrigine, 259
Lateral hypothalamus, 127, 625
L-DOPA, 515
Learned helplessness, 671
Learning, 613, 935
Lesions, 441
Lethality, 357
Lever press, 265
Life span study, 863
Light cigarettes, 539
Limited access paradigm, 31
Linoleic acid, 1047
Lipids, 377
Lipoproteins, 377
Lisuride, 383
Liver enlargement, 1047
L-NAME, 487
Locomotion, 363, 781, 839, 921, 1019
Locomotor activity, 111, 291, 327, 337, 383, 459, 473, 497, 593, 749
Locomotor behavior, 1005
Lorazepam, 69, 183
Lordosis, 417
Luteinizing hormone, 1011
Lymphocyte, 999

MA-631, 505
Macaca mulatta, 935
Macaque, 643
Maharishi Ayur-Ved, 505
Malaise, 601
Male sexual arousal, 1011
Maltose dextrin, 193
Maprotiline, 845
Marihuana, 715
MCI-225, 345
Mecamylamine, 749
Medial forebrain bundle, 557
Medial hypothalamus, 625
Medial prefrontal cortex, 671
Memory expression, 437
Memory, AMPA/kainate receptors in, 437
Memory, effects of CNQX on, 437
Mesencephalic central gray, 625
Mesolimbic, 521
Mesoprefrontal dopamine neurons, 297
Metabolic rate, 119
Metabolism, 543
Methadone, 47, 563
Methamphetamine, 587, 941
Methionine-enkephalin, 699
Methylphenidate, 773
Methysergide, 193, 411
Metyrapone, 977
Mice, 37, 69, 291, 677, 909, 959, 1031
Microdialysis, 605, 651, 671
Microinjection(s), 141, 315
Microsomal lipid peroxidation, 505
Midazolam, 357, 765
Middle cerebral artery occlusion, 77
MK-329, 479
MK-801, 9, 63, 161, 571, 587, 723, 935
(+)MK-801, 755
Monkey(s), 235, 723
Monoamine oxidase, 845
Monoamines, 621
Morphine, 127, 357, 563, 625, 677, 791
Morphine dependence, 363
Morphine physical dependence, 571
Motivation, 935
Motivational withdrawal signs, 1
Motor activity, 119, 465, 703, 899
Mouse strains, 497
Mouse striatum, 813
Mouse, 23, 689, 709, 965
Multiple schedule, 209, 491
Muscarinic receptors, 417

Naloxone, 363
Naloxone-precipitated opioid withdrawal, 1
Naloxone-precipitated withdrawal, 791
Naltrexone, 193, 709
Neonatal capsaicin, 447
Neuroleptanalgesia, 547
Neurological deficits, 77
Neuronal calcium channels, 77
Neuropeptide Y, 681
Neuroprotection, 77
Neurosteroids, 893
Nicotine, 37, 209, 521, 749
Nicotine discrimination, 817
Nicotine tolerance, 209
Nimodipine, 575
Nitric oxide, 487, 689, 799
Nitric oxide synthase inhibition, 689
Nitrous oxide, 689, 699
NMDA, 203, 291, 441
NMDA antagonists, 111, 755
NMDA receptor, 9
N-methyl-D-aspartate, 587
NNC 09-0026, 77
Noradrenaline, 307
Noradrenergic system, 93
Norepinephrine, 515, 525, 773, 1011
Novelty, 581
NPY, 1031
Nucleus accumbens, 141, 315, 651
Nutritional pharmacology, 101

Obesity, 57
Odorant recognition, 515
Olfactory bulb, 515
Oligemia, 613
1-(2-Pyrimidinyl)-piperazine, 301
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 235
Ontogeny, 781
Open field, 315
Open-field behaviours, 441
Operant behavior, 69, 935
Operant responding, 1
Opiate antagonists, 635
Opiate receptors, 677
Opioid(s), 47, 241, 357, 709
Oral ingestion, 563
Organic solvent, 661
Organophosphates, 643
Oscillating bar, 229
Ovariectomy, 265
Oxidative stress, 845
Oxotremorine, 703
Oxygen deficit, 613
Oxytocin, 203, 799

PA, 345
Palatability, 875
Pancreatic α-amylase, 371
Paradoxical sleep, 93
Paraventricular nucleus, 203
Paraventricular nucleus of the hypothalamus, 799
Partial agonists and antagonists, 281
Passive avoidance, 301
Penile erection, 203, 423, 799
Pentobarbital, 593
Pentylenetetrazol-induced seizures, 575
Phencyclidine, 77, 465, 941
Physical exercise, 377
Physical withdrawal signs, 1
Physostigmine, 417
Pigeons, 47, 183, 491
Pimozide, 253, 791
Place conditioning, 581
Place preference, 581
Placebo controlled, 899
Plus-maze, 497
Polydrug abuse, 715
Preference test, 479
Prefrontal cortex, 1053
Pregnenolone, 893
Pregnenolone sulfate, 893
Prenatal hypoxia exposure, 863
Primates, 259
Proadifen, 301
Probucol, 505
Proconvulsant drugs, 101
Prolactin, 429, 1011
Propionic acid, 371
Prostration, 749
Protein kinase, 813
Protein kinase C, 999
Punished responding, 491

Quinine, 875
Quinpirole, 781

Radial maze, 23
Rapid, 755
Rat fetus, 741
Rat social interaction, 223
Rat(s), 1, 87, 93, 111, 127, 135, 141, 203, 253, 259, 265, 281, 301, 307, 315, 351, 397, 453, 515, 521, 581, 651, 661, 699, 781, 787, 799, 881, 921, 941, 1019, 1025, 1041
Receptor, 429
Receptor binding, 111
Receptor subtypes, 241
Regional cerebral blood flow, 553
Reinforcement, 581
Reinforcement frequency, 941
Reinstatement, 217
Reinstatement of cocaine-taking behavior, 217
REM sleep deprivation, 43
Renin, 429
Reproduction, 909
Response duration differentiation, 941
Response force, 511
Restraint stress, 53
Reticular formation, 625
Reverse tolerance, 921
Reward, 487, 581
Righting reflex, 535
Ritanserin, 193, 315, 473
Ro 15-4513 binding, 223
Rotation, 441
R(+)-SCH-23390, 151
Running wheel, 839

Saccharin, 127, 723
Satiation, 809
Satiety, 479

SCH 23390, 327, 817, 853, 741
SCH23390, 43
Schedule-controlled behavior, 47, 265, 397, 511
Schedule-induced defection, 787
Schedule-induced plydipsia, 209
Scopolamine, 23, 161, 183, 345, 417
Scratching, 447
Self-administration, 217, 453, 473, 723, 1025
Self-stimulation, 853
Sensitivity, 229
Sensitization, 169, 307, 605, 791
Serotonergic 5-HT_{1B} agonist, 965
Serotonergic system, 665
Serotonin, 9, 105, 429, 525, 671, 875, 1011
Set point, 881
7-OH-DPAT, 531
Sexual behavior, 417
Sexual motivation, 929
Sexual reinforcement, 929
Shock postponement, 491
Short-term memory, 935
SKF 38393, 853
SKF-38393, 741
Smoking, 539
Sniffing, 135
Social isolation, 965
Sotalol, 971
Spatial memory, 613
Spatial working memory, 23
Spike-wave discharges, 547, 575
Spinal cord, 87
Spinal rats, 693
Spinal transection, 175
Spiperone, 383, 817, 853
Spontaneously hypertensive rat, 57
ST-91, 307
Startle, 453
Stereotyped behavior, 853
Stereotypy, 111, 169, 1053
Stimulation, 915
Stimulation-induced feeding, 557
Stress, 377
Striatum, 651, 681
Sucrose, 141, 193, 563, 875
Sulpiride, 43
Sweeteners, 991
Symptom relevant experience (SRE), 773

Tail flick, 175, 357, 693
Tandospirone, 805
Taste, 983, 991
Taste aversion, 275, 875
Taste conditioning, 1
Taste reactivity, 875
Temperature gradient, 881
Temperature regulation, 119
Temporal response differentiation, 935
Testosterone, 377
Tetrahydrocannabinol, 715
THA, 345
Thermoregulation, 881
Thiobarbituric acid-reactive substances, 505
[^{3}H]-MK 801, 351
[^{3}H]-SCH 23390, 351
[^{3}H]-spiroperidol binding studies, 351
Time course of sensitization, 921
Time estimation, 935
Tobacco, 539
Tolerance, 169, 253, 535, 587, 605, 755, 765
Toluene, 505
Tongue, 709
Tracking performance, 643
Trazodone, 845
Treadle pressing, 491
Tremor, 665
2,2′,2″-Tripyridine, 665

U50,488H, 63
U-50,488H, 87
Ultralight cigarettes, 539
Ultrasonic vocalisation, 301
Uric acid, 161

Vestibular reflexes, 535
Vitamin E, 505
Voltammetry, 161
Voluntary alcohol selection, 31
VTA, 1005

WAG/Rij rat, 547
Wakefulness, 899
Water maze, 345, 613
Well-being, 899
Wistar rats, 575
Wistar-Kyoto rat, 57
Withdrawal, 453, 723
Withdrawal syndrome, 363
Working memory, 183

Yawning, 203, 423, 799
Yohimbine, 307

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 48 1994

AUTHOR INDEX

Abekawa, T., 587
Abreu, M. E., 497
Acuff, C. G., 57
Adams, S. L., 941
Advokat, C., 175, 693
Akasofu, K., 423
Akunne, H. C., 411
Allen, R. R., 935
Alling, K., 511
Alvarez Sanz, M. C., 429
Andrew, R. J., 971
Andrews, N., 223
Argiolas, A., 203, 799
Asakura, W., 43
Askanazi, J., 101
Ates, N., 547, 575
Atrens, D. M., 853
Avery, D. D., 881

Bane, A. J., 881
Bardo, M. T., 459
Barnfield, A., 875
Barone, F. C., 77
Barrett, J. E., 491
Bartke, A., 1011
Bättig, K., 899
Beard, J. L., 621
Belzung, C., 23
Ben-Shahar, O., 1005
Bengtsson, A., 465
Beninger, 681
Beuzen, A., 23
Bhargava, H. N., 87
Bianchi, M., 1037
Bianchin, M., 437
Bidzinski, A., 315
Bielajew, C., 557
Black, M. D., 441
Blick, D. W., 644
Bondar, R. J., 193
Borlongan, C. V., 677
Bowling, S. L., 459
Bozarth, M. A., 487
Bratton, G. R., 543
Bresink, I., 111
Bronson, M. E., 397
Brown, G. C., 643
Buffalo, E. A., 935
Burke, T. F., 69
Burkey, R. T., 543
Burnham, W. M., 31
Bushnik, T., 557

Carmona, G. N., 723
Carney, J. M., 169, 733
Carrillo, P., 447
Carroll, M. E., 723, 1025
Caton, P. W., 689
Cazala, 625
Chakravarti, A. K., 53
Charrier, D., 281
Chau, A., 755
Chen, C.-J., 909
Chen, M. J., 773
Chen, Q., 621
Cleary, J., 47
Clemente, J., 805
Coen, K. M., 817
Coenen, A. M. L., 547
Cole, J. C., 959
Coleman, G. J., 563
Compton, A. D., 253
Connor, J., 621
Conti, L. H., 497
Cooper, S. J., 135
Coper, H., 863
Corrigall, W. A., 817
Costello, D. G., 497
Cottrell, G., 31
Covasa, M., 479
Crossman, A. R., 441
Cullen, W. K., 301

Dai, H., 921
Dall'Olio, R., 351
Damaj, M. I., 37
Dandiya, P. C., 845
Dangoumau, L., 281
Danysz, W., 111
Dark, K. A., 403
Darlington, C. L., 535
Darmani, N. A., 383
David, V., 625
Davies, A., 959
Davies, A. M., 875
Davies, B. T., 601
de Saint Hilaire-Kafi, Z., 93
Debray, M., 965
DeLeon, I., 787
DePetrillo, P. B., 999
Derrien, M., 363
Diana, G., 291
Dixon, M., 1041
Dluzen, D. E., 515
Dohanich, G. P., 417
Dougherty, T., 193
Dudek, B. C., 593
Duncan, W. C., Jr., 119

Egawa, M., 345
Eguchi, J., 345
Eina, H., 921
Ejantkar, A., 703
Elliott, P. J., 441
Elmaliah, S., 371
Emmett-Oglesby, M. W., 473
Engel, J. A., 977
Erb, S. M., 581
Erickson, R. P., 983
Erwin, V. G., 327
Espinoza, M., 791
Essmann, U., 111
Ettenberg, A., 929, 1005

Fahlke, C., 977
Falk, J. L., 209, 337
Feeney, D. M., 773
Fendt, M., 307
Feuerstein, G., 77
File, S. E., 223
Flood, J. F., 1031
Flores, R., 791
Forbes, J. M., 479
Frances, H., 965
Fukushima, T., 553
Fukuzako, H., 715
Furuse, M., 1047

Gagnon, M. J., 699
Gaillard, J.-M., 93
Gandolfi, O., 351
Gatlin, L. A., 983
Gerdes, C. F., 383
Gher, J., 1011
Ghorpade, A., 175, 693
Gibbs, J., 809
Gillam, M. P., 935
Gordon, C. J., 119, 703
Grady, D. R., 105
Grover, C. A., 543
Guan, X., 515
Gyorda, A. M., 491

Halsey, M. J., 259
Hamon, M., 281
Hanna, A. N., 505
Hansen, S., 977
Hara, S., 699
Haraguchi, M., 141
Hård, E., 977
Hardwick, W. C., 941
Hatipoğlu, I., 571
Hay, M., 563
Hayes, A. G., 441
Heim, C., 613
Heiman, S. A., 983
Higgins, G. A., 1
Higgins, G. A., 1019
Hiramatsu, M., 9
Hisada, K., 553
Hodge, C. W., 141
Hoebel, B. G., 651
Höfer, I., 899
Hsu, K.-S., 665
Hunt, G. E., 853

Ida, Y., 297
Inoue, M., 547
Islam, A. K., 193
Israel, Y., 229
Izquierdo, I., 437

Jackson, D. M., 465, 853
Jaehkel, M., 839
Jakobsen, P., 77
Jänicke, B., 863
Jaskiw, G. E., 1053
Jessa, M., 315
Jibiki, I., 553
Jin, C.-B., 57
Johansson, C., 465
Jones, B. C., 327, 621

Kalant, H., 755
Kameyama, T., 9
Katner, J. S., 525
Kauffman, E. M., 505
Kelley, A. E., 915
Khanna, J. M., 755
Kirkham, T. C., 809
Kline, A. E., 773
Koch, J. E., 193
Koch, M., 307
Kostal, L., 241
Kostowski, W., 315
Kouri, E., 715
Kovera, C. A., 47
Koyama, T., 587
Koyuncuoğlu, H., 571
Kozlowski, L. T., 539
Kramer, G., 671
Krug, D., 161
Kunimoto, K., 429
Kunko, P. M., 161
Kurokawa, K., 553

Lac, S. T., 1025
Lau, C. E., 209, 337
Lê, A. D., 229
Leban, J., 809
Leblanc, J., 887
LeSage, M., 787
Levy, A. D., 429
Li, Q., 429
Lin-Shiau, S.-Y., 665
Lindgren, L.-M., 465
Linseman, M. A., 31
Lipska, B. K., 1053

Losee M. L., 991
Lukas, S. E., 715

Maclean, C. J., 259
Makhay, M., 511, 787
Maldonado, R., 363
Maldonado-Irizarry, C. S., 915
Manner, T., 101
Mansbach, R. S., 453
Manzo, J., 447
Mark, G. P., 651
Markou, A., 453
Martin, B. R., 37
Martin, L. A., 497
Martinez-Gomez, M., 447
Mastrangelo, D., 93
Matsuda, H., 553
Matsuguchi, N., 297
Matsumoto, K., 43
Matwyshyn, G. A., 87
McClure, G. Y. H., 941
McDermed, J., 809
McEldowney, S. S., 423
McElroy, J. F., 531
McLachlan, C. D., 563
McLaughlin, P. J., 709
McMahon, L. R., 601
McMillan, D. E., 941
Medina, J. H., 437
Meil, W., 605
Melchoir, C. L., 893
Meldrum, B. S., 259
Melis, M. R., 203, 799
Melton, P. M., 275
Menard, C. S., 417
Mendelson, J. H., 715
Merali, Z., 681
Meyer, M. E., 781
Miles, C., 875
Miller, L. G., 69
Mock, O. B., 383
Moeller, M., 671
Moerschbaecher, J. M., 69
Mokler, D. J., 1041
Monier, C., 965
Moore, E., 681
Morato, G. S., 755
Morien, A., 601
Morley, J. E., 1031
Morris, M., 487
Morse, A. C., 539
Moufid-Bellancourt, S., 127
Mueller, K., 161
Munirathinam, G., 813
Murai, A., 1047
Muraki, A., 587
Murphy, L. L., 1011
Murphy, M. R., 643
Museo, E., 521
Mustafa, S., 921

Nabeshima, T., 9
Nagy, J., 17
Nation, J. R., 543
Nazar, M., 315
Nencini, P., 63
Newman, H. A. I., 505

Oehler, J., 839
Ohmori, T., 587
Ohta, H., 43
Okumura, J.-I., 1047
Olster, D. H., 929
Overmier, J. B., 47, 183
Overstreet, D. H., 703

Pacheco, P., 447
Pal, S. N., 845
Palejko, W., 315
Panerai, A. E., 1037
Parker, L. A., 581, 875
Patrick, G. A., 453
Paule, M. G., 935
Pearce, P. C., 259
Peeke, H. V. S., 403
Peltier, R. L., 473
Petersen, A. J., 101
Petrov, E. S., 741
Petty, F., 671
Pillitteri, J. L., 539
Pinchasov, Y., 371
Plaznik, A., 315
Poling, A., 511, 787
Porter, J. H., 253
Potter, T. J., 781
Price, W. J., 77
Pudiak, C. M., 487
Puech, A. J., 281
Puri, S., 53

Quartermain, D., 805
Quillfeldt, J. A., 437
Quock, R. M., 689, 699

Racotta, I. S., 887
Rada, P. V., 651
Ramsey-Williams, V. A., 765
Rattan, A. K., 357
Ray, A., 53
Reddy, P. L., 87
Reid, K., 57
Rezvani, A. H., 105
Rezvani, A. H., 703
Richard, D., 887
Riley, A. L., 275, 635
Rimondini, R., 351
Rittenhouse, P. A., 429
Ritzmann, R. F., 893
Robinson, S. R., 741
Rockhold, R. W., 57
Rodefer, J. S., 723
Rodgers, R. J., 959
Roeltgen, D. P., 235
Roques, B. P., 363
Rosenberg, H. C., 765
Roullet, P., 23
Rowan, M. J., 301
Rusche, W. P., 525

Sacerdote, P., 1037
Sachs, B. D., 423
Sagratella, S., 291
Sajdyk, T. J., 525
Salamy, A., 403
Salas, M., 447
Salfi, M., 403
Samson, H. H., 141
Saponjic, R. M., 161
Sarica, Ö., 571
Savage, L. M., 183
Savory, C. J., 241
Schaal, D. W., 47
Schenk, S., 217, 473
Scherrer, J., 1031
Schiffman, S. S., 983, 991
Schmitz, P. K., 437
Schneider, J. S., 235
Schnitzler, H.-U., 307
Schnur, P., 791
Schumacher, H. E., 839
Scott, M. P., 929
See, R. E., 605
Sellers, E. M., 1, 1019
Sen, P., 53
Sgouraki, E., 377
Shah, G., 755
Shah, S. N., 403
Sharma, H. M., 505
Sheardown, M. J., 77
Shekhar, A., 525
Shemer, A., 805
Shergill, H. K., 259
Shibuya, T., 699
Shirao, I., 297
Shoaib, M., 749
Sholar, M., 715
Sieklucka, M., 613
Sills, T. L., 1019
Simon, J. R., 525
Skeie, B., 101
Smith, G. P., 809
Smith, P. F., 535
Smith, S. E., 651
Smotherman, W. P., 741
Smurthwaite, S. T., 635
Soliman, K. F. A., 411
Sontag, K.-H., 613
Spear, D. J., 209
Specker, S. M., 1025
Sribanditmongkol, P., 357
Stagner, W. C., 983
Stalikas, A., 377
Stambaugh, L., 1041
Stancampiano, R., 203, 799
Stanchfield, M. A., 183
Steen, P. A., 101
Stefanski, R., 315
Steger, R. W., 1011
Stellar, J. R., 915
Stephenson, R. M., 971
Stolerman, I. P., 749
Stump, B. S., 881
Suggs, M. S., 983, 991
Sullivan, R. M., 921
Sun, Z.-Q., 235
Szechtman, H., 921

Tatham, T. A., 491
Tejedor-Real, P., 363
Tella, S. R., 151
Thiébot, M.-H., 281
Thomas, W. H., 473
Thomasson, R., 977
Thompson, T., 47
Tindley, G., 259
Tobe, A., 345
Tolliver, B. K., 169, 733
Tolliver, G. A., 141
Tomkins, D. M., 1019
Tousman, S. A., 689
Towns, L. C., 383
Tritto, T., 593
Tso-Olivas, D. Y., 773
Tsopanakis, A., 377
Tsopanakis, C., 377
Tsuji, S., 553
Tsujimaru, S., 297

Underwood, K. A., 593

Vaccarino, F. J., 1019
Valadez, A., 217
Valeri, P., 63
Valverde, O., 363
van de Kar, L. D., 429
van der Hoek, G. A., 135
van der Staay, F. J., 575
van Haaren, F., 265
van Hartesveldt, C., 781
van Luijtelaar, E. L. J. M., 575
Vandenbergh, J. G., 909
Varlinskaya, E. I., 741
Veeranna, 87
Velley, L., 127
Vossen, J. M. H., 547

Walsh, C. A., 809
Walz, R., 437
Ward, E. M., 259
Watanabe, H., 43
Watanabe, S., 677
Weathersby, D. W., JR., 643
Weinberger, D. R., 1053
Welch, S. P., 37
Wellman, P. J., 601
Wenger, G. R., 941
White, M. F., 497
Wiley, J. L., 253
Wilke, R., 111
Wise, R. A., 521
Wolfe, E., 693
Womer, D. E., 327
Worley, C. M., 217
Wu, Y., 709, 765

Yamaguchi, N., 553
Yavich, L., 661
Yoburn, B. C., 813
Yokoyama, S., 9
Yracheta, J. M., 429
Yuasa, T., 345

Zagon, I. S., 709
Zanatta, M. S., 437
Zhang, T., 57
Zvartau, E., 661